| Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer HI Scher, D Lu, NA Schreiber, J Louw, RP Graf, HA Vargas, A Johnson, ... JAMA oncology 2 (11), 1441-1449, 2016 | 640 | 2016 |
| Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: the PROPHECY study AJ Armstrong, S Halabi, J Luo, DM Nanus, P Giannakakou, ... Journal of Clinical Oncology 37 (13), 1120, 2019 | 306 | 2019 |
| Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations F Karzai, D VanderWeele, RA Madan, H Owens, LM Cordes, A Hankin, ... Journal for immunotherapy of cancer 6, 1-12, 2018 | 242 | 2018 |
| Assessment of the validity of nuclear-localized androgen receptor splice variant 7 in circulating tumor cells as a predictive biomarker for castration-resistant prostate cancer HI Scher, RP Graf, NA Schreiber, A Jayaram, E Winquist, B McLaughlin, ... JAMA oncology 4 (9), 1179-1186, 2018 | 219 | 2018 |
| Safety and efficacy of BIND-014, a docetaxel nanoparticle targeting prostate-specific membrane antigen for patients with metastatic castration-resistant prostate cancer: a … KA Autio, R Dreicer, J Anderson, JA Garcia, A Alva, LL Hart, MI Milowsky, ... JAMA oncology 4 (10), 1344-1351, 2018 | 197 | 2018 |
| Nuclear-specific AR-V7 protein localization is necessary to guide treatment selection in metastatic castration-resistant prostate cancer HI Scher, RP Graf, NA Schreiber, B McLaughlin, D Lu, J Louw, DC Danila, ... European urology 71 (6), 874-882, 2017 | 174 | 2017 |
| Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer K Boudadi, DL Suzman, V Anagnostou, W Fu, B Luber, H Wang, ... Oncotarget 9 (47), 28561, 2018 | 144 | 2018 |
| Impact of molecular subtyping and immune infiltration on pathological response and outcome following neoadjuvant pembrolizumab in muscle-invasive bladder cancer A Necchi, D Raggi, A Gallina, JS Ross, E Farè, P Giannatempo, ... European urology 77 (6), 701-710, 2020 | 141 | 2020 |
| The initial detection and partial characterization of circulating tumor cells in neuroendocrine prostate cancer H Beltran, A Jendrisak, M Landers, JM Mosquera, M Kossai, J Louw, ... Clinical Cancer Research 22 (6), 1510-1519, 2016 | 141 | 2016 |
| Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer L Puca, K Gavyert, V Sailer, V Conteduca, E Dardenne, M Sigouros, ... Science translational medicine 11 (484), eaav0891, 2019 | 126 | 2019 |
| Phenotypic heterogeneity of circulating tumor cells informs clinical decisions between AR signaling inhibitors and taxanes in metastatic prostate cancer HI Scher, RP Graf, NA Schreiber, B McLaughlin, A Jendrisak, Y Wang, ... Cancer research 77 (20), 5687-5698, 2017 | 123 | 2017 |
| Analytical validation and capabilities of the epic CTC platform: enrichment-free circulating tumour cell detection and characterization SL Werner, RP Graf, M Landers, DT Valenta, M Schroeder, SB Greene, ... Journal of Circulating Biomarkers 4, 3, 2015 | 122 | 2015 |
| Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients A Anantharaman, T Friedlander, D Lu, R Krupa, G Premasekharan, ... BMC cancer 16, 1-11, 2016 | 121 | 2016 |
| Cellular expression of PD-L1 in the peripheral blood of lung cancer patients is associated with worse survival DJ Boffa, RP Graf, MC Salazar, J Hoag, D Lu, R Krupa, J Louw, L Dugan, ... Cancer Epidemiology, Biomarkers & Prevention 26 (7), 1139-1145, 2017 | 76 | 2017 |
| Circulating tumor cells (CTC) and cell-free DNA (cfDNA) workshop 2016: scientific opportunities and logistics for cancer clinical trial incorporation LE Lowes, SV Bratman, R Dittamore, S Done, SO Kelley, S Mai, RD Morin, ... International Journal of Molecular Sciences 17 (9), 1505, 2016 | 74 | 2016 |
| Phenotypic diversity of circulating tumour cells in patients with metastatic castration‐resistant prostate cancer AS McDaniel, R Ferraldeschi, R Krupa, M Landers, R Graf, J Louw, ... BJU international 120 (5B), E30-E44, 2017 | 68 | 2017 |
| Clinical utility of the nuclear-localized AR-V7 biomarker in circulating tumor cells in improving physician treatment choice in castration-resistant prostate cancer RP Graf, M Hullings, ES Barnett, E Carbone, R Dittamore, HI Scher European urology 77 (2), 170-177, 2020 | 63 | 2020 |
| Single-cell circulating tumor cell analysis reveals genomic instability as a distinctive feature of aggressive prostate cancer PD Malihi, RP Graf, A Rodriguez, N Ramesh, J Lee, R Sutton, R Jiles, ... Clinical Cancer Research 26 (15), 4143-4153, 2020 | 56 | 2020 |
| SLFN11 expression in advanced prostate cancer and response to platinum-based chemotherapy V Conteduca, SY Ku, L Puca, M Slade, L Fernandez, J Hess, R Bareja, ... Molecular cancer therapeutics 19 (5), 1157-1164, 2020 | 55 | 2020 |
| Chromosomal instability estimation based on next generation sequencing and single cell genome wide copy number variation analysis SB Greene, AE Dago, LJ Leitz, Y Wang, J Lee, SL Werner, S Gendreau, ... PLoS One 11 (11), e0165089, 2016 | 47 | 2016 |
